Home » Clinical Trials » Solid tumors » NCT06612645
NCT06612645

Safety and Efficacy of B7H3 With IL-7 Receptor Alpha Signaling Chimeric Antigen Receptor T Cell (CMD03) in Relapse and Refractory Pediatric Solid Tumors

Study Summary

A Phase 1 clinical trial to evaluate the safety and early efficacy of CAR T-cells with IL-7Ra signal targeting B7H3 in children with solid tumors patients after complete standard treatments.

Want to learn more about this trial?

Request More Info

Interventions

B7H3-IL7Ra CAR-T cellsBIOLOGICAL
Autologous T cells lentiviral transduced to express a B7H3-specific chimeric antigen receptor (CAR) with the addition of an IL-7 receptor alpha signaling domain, administered via central venous access catheter after lymphodepletion

Study Locations

FacilityCityStateCountry
King Chulalongkorn Memorial HospitalBangkokPathumwanThailand

Official Trial Information

View on ClinicalTrials.gov

Data sourced from ClinicalTrials.gov. Last updated: April 14, 2026